Used in research and development for targeted cancer immunotherapies, particularly in melanoma. Binds specifically to the TYRP1 (tyrosinase-related protein 1) antigen, which is highly expressed in melanocytes and melanoma cells. This selective binding enables its use in studying tumor targeting, antibody-drug conjugates, and immune cell engagement strategies. Also serves as a reference standard in assay development, biomarker detection, and evaluation of therapeutic antibody performance.